EPJ Web Conf.
Volume 231, 20208th International Meeting of Union for Compact Accelerator-Driven Neutron Sources (UCANS-8)
|Number of page(s)||5|
|Published online||11 March 2020|
Diffusion bonded Be neutron target using 8MeV proton beam
High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
* Corresponding author: firstname.lastname@example.org
Published online: 11 March 2020
The development of the high intensity compact neutron source is mainly conducted by using accelerators for medical purposes. Recently, a lot of compact neutron sources have been developed, and most of them are for boron neutron capture therapy (BNCT). Compared with the common accelerators used for industries, accelerators for BNCT have to accelerate a 100 times larger current of charged particles because of the low conversion efficiency of neutron moderators. To attain a reliable target for the BNCT neutron source, two obstacles have to be overcome; radiation damage (blistering) and heat issue. We introduce diffusion bonding method aiming to make defect free Be neutron target and 1 MPa latent heat water-cooling system. We also install beam expansion optics using quadrupole and octupole magnets to reduce the charge density. Our facility has been operating for more than three years from the commissioning period and we report the recent situation as following. 1) Diffusion bonding method was applied to the solid neutron target of Be with latent heat cooling system. 2) Amount of integrated coulomb value of protons implanted to the Be target is nearly 3000 C now 3) Amount of neutron dose rate was measured. 4) A laser reflection microscope (LRM) method has been developed to observe the neutron target condition (especially radiation damage) through viewport with a few meters working distance. 5) Direct observation of the surface of the Be target was done during the period of improving nearly target vacuum and residual radiation conditions. From these evidences, we conclude our neutron target already produces neutrons capable to treat nearly 500 patients of malignant melanoma.
© The Authors, published by EDP Sciences, 2020
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.